Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

USRE47690E1 · kind E1 · reissue

Assignee

• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• Xuedong Liu · San Jose, US
• Gan Zhang · Boulder, US
• Daniel Chuen-Fong Chan · Denver, US
• Anthony D. Piscopio · Longmont, US

Key dates

• Filing date: May 1, 2018
• Grant date: Nov 5, 2019
• Expiry date: May 1, 2038

Classification

• Technology area (CPC —): General

Abstract

The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.